It isn’t easy to change the way an industry thinks, but NovaQuest and Solvay have established an innovative arrangement that transforms the traditional fee-for-service clinical arrangement into a true alliance of mutual interests.

Situation

Solvay had several promising Phase III products, including one for irritable bowel syndrome that required an accelerated schedule due to competitive activity. The unexpected increase in Solvay’s costs threatened its investment in its Phase II pipeline.

Solution

NovaQuest and Solvay worked together to solve the problem through a multi-part strategic and co-investment alliance.

First, NovaQuest and Quintiles established a Master Services Agreement that gives Solvay access to state-of-the-art clinical trial execution at competitive, volume-dependant prices. The relationship simplifies and accelerates study start-up, and reduces both Quintiles’ learning curve and the delays often caused by contract negotiations for each new project. This streamlined operational relationship benefited not only the irritable bowel Phase III program but also other development opportunities at Solvay. 

Second, NovaQuest and Solvay agreed to a services partnership to help fund Solvay’s Phase II portfolio. NovaQuest funds professional fees for up to 10 proof of principle studies over three years, so Solvay can afford to process more assets through its Phase II pipeline.

In return, NovaQuest receives milestone payments triggered by successful proof of principle studies. This helps match Solvay’s out-of-pocket costs with the increased value of its assets.

Value Added

With this customized operational and co-investment relationship in place, Solvay, NovaQuest and Quintiles are firmly aligned to optimize the speed, cost and quality of clinical development programs across Solvay’s portfolio.